Red flag for Bharat Biotech Contract?

1593809007 1781
Image Credit: Business Standard

According to a document seen by Reuters on Tuesday, Brazilian federal prosecutors have opened an investigation into a contract worth $320 million for 20 million doses of Covaxin made by Bharat Biotech. The prosecutor-general’s office (PGR) cited comparatively high prices, speedy talks and pending regulatory approvals, posing red flags for the Bharat Biotech contract signed in February. Earlier this month, the pharma company had also drawn critical observation from a Brazilian Senate inquiry, which called for the head of Precisa Medicamentos (Bharat’s intermediary in Brazil) to give testimony about the same. In a statement, the company clarified that the price of Bharat Biotech’s vaccine in Brazil was the same as charged in more than a dozen other countries.

Astha Gupta is an editor at Surkhiyaa. Sensitive to her surroundings, Astha is a keen content writer who aspires to bring you all to-the-point information. She believes in honest journalism and hopes that her work becomes the reason for people to look at things from a whole new perspective. Astha can be reached out at .

Leave a Reply

Your email address will not be published.

Translate »
%d bloggers like this: